Q4 2013 18 Jun 2013 13:46
Ali Mortazavi, Silence’s chief executive, added: "With the completion of Atu027 phase I study and a strengthened cash position, Silence Therapeutics is now ready to embark on the next step in a road well-trodden by the pioneers of the biotechnology industry."
Speaking to Proactive Investors, he said an upcoming milestone would be a day organised in the fourth quarter where the firm would be able to outline a new-look Silence to analysts, having redesigned its drug pipeline, systems, forecasts and costings.
"A £100 million company has to give, if you like, the Street some idea of who and what it is."
"We'll be using the same core technology, however, he points out, referring to the gene silencing technology.
"That can never change and we have one drug in the clinic as we speak but we are going to have a second indication in our lead drug Atu027 and we are going to come out with two or three other ideas."